S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82

Biofrontera Stock Forecast, Price & News

-0.37 (-8.64%)
(As of 11/30/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
52,753 shs
Average Volume
49,860 shs
Market Capitalization
$110.88 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive BFRA News and Ratings via Email

Sign-up to receive the latest news and ratings for Biofrontera and its competitors with MarketBeat's FREE daily newsletter.

Biofrontera logo

About Biofrontera

Biofrontera AG engages in the development, sale and distribution of dermatological drugs and medical cosmetics for the care, protection and treatment of the skin. Its products include Ameluz, BF-RhodolesXepi and Belixos. The company was founded by Hermann Lübbert in 1997 and is headquartered in Leverkusen, Germany.


Biofrontera Inc. Gains Another 51% - MarketWatch
November 28, 2021 |  marketwatch.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$36.19 million
Book Value
$0.35 per share


Net Income
$-14.88 million
Pretax Margin




Free Float
Market Cap
$110.88 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

0.88 out of 5 stars

Medical Sector

1296th out of 1,390 stocks

Pharmaceutical Preparations Industry

631st out of 669 stocks

Analyst Opinion: 0.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Biofrontera (NASDAQ:BFRA) Frequently Asked Questions

How has Biofrontera's stock price been impacted by COVID-19?

Biofrontera's stock was trading at $9.28 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BFRA shares have decreased by 57.9% and is now trading at $3.91.
View which stocks have been most impacted by COVID-19

Are investors shorting Biofrontera?

Biofrontera saw a increase in short interest in November. As of November 15th, there was short interest totaling 2,600 shares, an increase of 2,500.0% from the October 31st total of 100 shares. Based on an average daily trading volume, of 22,500 shares, the short-interest ratio is presently 0.1 days.
View Biofrontera's Short Interest

When is Biofrontera's next earnings date?

Biofrontera is scheduled to release its next quarterly earnings announcement on Monday, April 11th 2022.
View our earnings forecast for Biofrontera

How were Biofrontera's earnings last quarter?

Biofrontera AG (NASDAQ:BFRA) released its earnings results on Wednesday, November, 24th. The company reported ($0.24) EPS for the quarter, missing the Zacks' consensus estimate of ($0.22) by $0.03. Biofrontera had a negative trailing twelve-month return on equity of 93.31% and a negative net margin of 59.44%.
View Biofrontera's earnings history

How often does Biofrontera pay dividends? What is the dividend yield for Biofrontera?

Biofrontera declared a -- dividend on Thursday, February 18th. Shareholders of record on Thursday, February 25th will be given a dividend of $0.1039 per share on Thursday, March 4th. The ex-dividend date of this dividend is Wednesday, February 24th. This is a boost from Biofrontera's previous -- dividend of $0.02.
View Biofrontera's dividend history

What guidance has Biofrontera issued on next quarter's earnings?

Biofrontera updated its FY 2021 earnings guidance on Thursday, November, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $29.48 million-$37.73 million, compared to the consensus revenue estimate of $35.15 million.

Who are Biofrontera's key executives?

Biofrontera's management team includes the following people:
  • Hermann Lübbert, Chairman-Management Board & CEO
  • Ludwig Lutter, Chief Financial Officer
  • Pamela Keck, Investor Relations Contact

What other stocks do shareholders of Biofrontera own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biofrontera investors own include AbbVie (ABBV), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Adaptimmune Therapeutics (ADAP), (AZN), GW Pharmaceuticals (GWPH), Pfizer (PFE), Alnylam Pharmaceuticals (ALNY) and Ascendis Pharma A/S (ASND).

When did Biofrontera IPO?

(BFRA) raised $18 million in an IPO on Wednesday, February 14th 2018. The company issued 1,500,000 shares at $11.00-$13.00 per share. Benchmark acted as the underwriter for the IPO and Dawson James Securities and Lake Street Capital Markets were co-managers.

What is Biofrontera's stock symbol?

Biofrontera trades on the NASDAQ under the ticker symbol "BFRA."

Who are Biofrontera's major shareholders?

Biofrontera's stock is owned by many different institutional and retail investors. Top institutional investors include Morgan Stanley (0.05%) and Citadel Advisors LLC (0.04%).

Which major investors are selling Biofrontera stock?

BFRA stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, and Citadel Advisors LLC.

How do I buy shares of Biofrontera?

Shares of BFRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biofrontera's stock price today?

One share of BFRA stock can currently be purchased for approximately $3.91.

How much money does Biofrontera make?

Biofrontera has a market capitalization of $110.88 million and generates $36.19 million in revenue each year. The company earns $-14.88 million in net income (profit) each year or ($0.73) on an earnings per share basis.

How many employees does Biofrontera have?

Biofrontera employs 138 workers across the globe.

What is Biofrontera's official website?

The official website for Biofrontera is www.biofrontera.com.

Where are Biofrontera's headquarters?

Biofrontera is headquartered at HEMMELRATHER WEG 201, LEVERKUSEN 2M, D-51377.

How can I contact Biofrontera?

Biofrontera's mailing address is HEMMELRATHER WEG 201, LEVERKUSEN 2M, D-51377. The company can be reached via phone at (921) 487-6320, via email at [email protected], or via fax at 49-02-1487-6320.

This page was last updated on 12/1/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.